CIK 0000318154 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2022 | FY2021 | |
|---|---|---|---|---|
| Revenue (USD) | 36.8 B | 26.3 B | ||
| Net income (USD) | 7.3 B | 7.8 B | ||
| Diluted EPS (USD/shares) | 14.23 | 12.11 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-09-04 | 3 | PRIMARY DOCUMENT | 2026-09-01 |
| 2026-08-13 | 4 | PRIMARY DOCUMENT | 2026-08-11 |
| 2026-08-13 | 144 | 144 | |
| 2026-08-12 | 4 | PRIMARY DOCUMENT | 2026-08-07 |
| 2026-08-11 | 144 | 144 | |
| 2026-08-10 | 4 | PRIMARY DOCUMENT | 2026-08-07 |
| 2026-08-10 | 4 | PRIMARY DOCUMENT | 2026-08-07 |
| 2026-08-10 | 4 | PRIMARY DOCUMENT | 2026-08-07 |
| 2026-08-07 | 4 | PRIMARY DOCUMENT | 2026-08-06 |
| 2026-08-07 | 4 | PRIMARY DOCUMENT | 2026-08-06 |
| 2026-08-06 | 144 | 144 | |
| 2026-08-06 | 144/A | 144/A | |
| 2026-08-06 | 144 | 144 | |
| 2026-08-05 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-04 | 8-K | 8-K items 2.02,9.01 | 2026-08-04 |
| 2026-07-31 | 8-K | 8-K items 1.05 | 2026-07-29 |
| 2026-06-11 | 11-K | 11-K | 2025-12-31 |
| 2026-06-11 | 11-K | 11-K | 2025-12-31 |
| 2026-05-21 | 4 | PRIMARY DOCUMENT | 2026-05-19 |
| 2026-05-21 | 4 | PRIMARY DOCUMENT | 2026-05-19 |
| 2026-05-21 | 4 | PRIMARY DOCUMENT | 2026-05-19 |
| 2026-05-21 | 4 | PRIMARY DOCUMENT | 2026-05-19 |
| 2026-05-21 | 4 | PRIMARY DOCUMENT | 2026-05-19 |
| 2026-05-21 | 4 | PRIMARY DOCUMENT | 2026-05-19 |
| 2026-05-21 | 4 | PRIMARY DOCUMENT | 2026-05-19 |
Forms on file (last 1,000): 4 672, 8-K 92, DEFA14A 31, SC 13G/A 27, 144 25, 10-Q 25, 3 19, 11-K 18. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=AMGN (0.002 USD), /gw/filings/filings?ticker=AMGN&form=8-K, /gw/filings/facts?ticker=AMGN&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange